Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Breast Neoplasms 81Carcinoma, Non-Small-Cell Lung 41Colonic Neoplasms 40Lung Neoplasms 39Leukemia 36Rectal Neoplasms 34Lymphoma 34Colorectal Neoplasms 33Prostatic Neoplasms 24Multiple Myeloma 23Lymphoma, Follicular 22Leukemia, Myeloid, Acute 19Ovarian Neoplasms 18Lymphoma, Non-Hodgkin 18Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Large B-Cell, Diffuse 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Melanoma 16Head and Neck Neoplasms 15Urinary Bladder Neoplasms 14Neoplasms, Plasma Cell 14Lymphoma, Large-Cell, Immunoblastic 14Burkitt Lymphoma 14Squamous Cell Carcinoma of Head and Neck 12Pancreatic Neoplasms 12Myelodysplastic Syndromes 12Leukemia, Myelomonocytic, Acute 12Leukemia, Monocytic, Acute 12Leukemia, Megakaryoblastic, Acute 12Leukemia, Erythroblastic, Acute 12

Interventions

Sorafenib 1Mitoxantrone 1Leyk 1Etoposide 1Daunorubicin 1Cytarabine 1Bortezomib 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × NIH × Sarcoma, Myeloid × Clear all
NCT01371981 2026-06-02

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
1,645 enrolled 32 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡